Helix BioPharma Corp. Announces Interim Financial Results

Toronto, Ontario — June 16, 2025 — NewsWall —

Helix BioPharma Corp. (TSX:HBP, OTC PINK:HBPCD, FRANKFURT:HBP0) has announced the filing of its unaudited interim financial statements for the nine-month period ended April 30, 2025. The interim filings, which include the financial statements, management’s discussion and analysis, and certifications from the CEO and CFO, are available on the company’s profile at www.sedarplus.ca.

Helix BioPharma is a clinical-stage oncology company focused on developing near-term solutions for hard-to-treat cancers. Its pipeline is led by Tumor Defense Breaker™ L-DOS47, an antibody-enzyme conjugate in clinical stage designed to increase sensitivity to therapy for CEACAM6-expressing tumors.

The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug.

Jacek Antas, Director, can be reached at corporate@helixbiopharma.com or +1 857 208 7687.

Source: Helix BioPharma